2025 has seen 43 novel FDA drug approvals – new drugs never before approved or marketed in the U.S – introducing high-impact therapies that are redefining what “breakthrough” truly means. This year’s portfolio highlights durable formulations…
🦃 This holiday season, we’re especially grateful for partnerships that bring hope to patients and families. We are honored to power the AI-based clinical trial finder for ALK Positive, a patient-driven organization dedicated to improving the…
In 2022, OpenAI launched its first large-scale AI tool—an innovation that quickly reshaped how industries approached automation, creativity, and problem-solving. Since then, artificial intelligence has become part of everyday workflows, turning time-intensive tasks into faster, data-driven…
Artificial Intelligence (AI) has become one of the most talked-about innovations in clinical research, driving advances in everything from patient recruitment to data analysis. The field is now evolving further with the rise of agentic AI—systems…
Throwback to October 13th! We were honored to power the Clinical Trial Finder for the groundbreaking Reflections initiative, a program transforming how communities engage with clinical research. Designed to enhance diversity in clinical trials and raise…
The 15th annual DPHARM: Disruptive Innovations to Modernize Clinical Research (September 16–17, 2025, Philadelphia, PA) brought together senior clinical operations executives, patient advocates, and technology leaders to explore the future of clinical trials. AI, patient-centric trial…
ALS, or amyotrophic lateral sclerosis, is a progressive neurodegenerative disease that affects nerve cells controlling voluntary muscle movement. Each year, more than 5,000 people in the United States are diagnosed, and around 30,000 people are living…
